Come, let us spread flowers and pour wine into the pitcher;
Let us split the sky and devise a new plan
— Hafez, Persian poet, 1325 - 1390 AD
More than a decade ago, an idea took shape: A journal devoted exclusively to the translational interface of cellular, molecular, and clinical anesthesiology at a time when such integration was still rare. In January 2016, that vision became reality with the launch of the Journal of Cellular and Molecular Anesthesia (JCMA).
From the outset, JCMA sought not merely to add another title to the literature but to create a genuine bridge between laboratory discovery and bedside application (1). Over the past ten years, the journal has worked to foster dialogue between basic scientists and clinicians, promote hypothesis-driven research, and nurture a robust translational framework within our specialty. None of this would have been possible without rigorous peer review, editorial discipline, and the sustained commitment of an expanding international community.
The journal’s development has rested on the contributions of many. The editorial board and staff have provided steadfast guidance through the changing landscape of scientific publishing. In particular, the unwavering dedication of our two associate editors, Dr. Firoozeh Madadi and Dr. Samira Rajaei, merits special acknowledgment. Throughout these years, their scientific insight, editorial judgment, and tireless engagement have been indispensable in shaping JCMA’s identity and maintaining its standards.
We also express our deepest gratitude to Dr. Hedayatollah Elyassi, the pioneering scientific elder Chief of the Anesthesiology Department, Shahid Beheshti University of Medical Sciences (SBMU); to Dr. Sajad Razavi, then-Chief of the Department of Anesthesiology at SBMU during the journal’s formative epoch; and to Dr. Forouzan Karimi, Officer in Charge of the Scientific Journals at SBMU. Strategic collaboration with Brieflands Publishing later brought essential infrastructure and operational efficiency, allowing JCMA to manage its growing international portfolio with greater professionalism. Equally vital have been our authors, reviewers, and readers, representing North America, Europe, the Middle East, Asia, and beyond, who have collectively elevated the standards of translational scholarship in our field. The contributors of the First Congress of Translational Anesthesiology in Association with Tech-Talk also helped develop the concept both at the national and international level (2).
As we cross the threshold into our second decade, we do so not to maintain the status quo, but to redefine what is possible in translational anesthesiology.
The next ten years will not be about incremental progress; they will be about bold transformation. JCMA should strive to be the global leader in publishing translational research that moves directly and decisively from mechanism to meaningful clinical change. We will champion large-scale multidisciplinary consortia, demand reproducible science of the highest rigor, and accelerate the translation of molecular discoveries into therapies that redefine perioperative outcomes, neuroprotection, organ preservation, and critical care survival. We declare that within this decade, work first published in JCMA should contribute directly to new clinical guidelines, novel therapeutics, and measurable reductions in perioperative morbidity and mortality worldwide.
The first decade built the platform. The second decade will change patients’ lives.
We invite every researcher, clinician, and innovator who shares this uncompromising vision to join us. The future of anesthesiology is translational, and that future begins here.
